[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 266
6. Barrett AJ, Le Blanc K: Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol; 2010 Aug;161(2):223-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy prospects for acute myeloid leukaemia.
  • While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse.
  • Evidence for immunosurveillance of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction.
  • Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents.
  • Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure.
  • [MeSH-major] Immunotherapy / methods. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):483-4 [18938742.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4934-9 [18591543.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5192-7 [18854573.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2187-95 [19021063.001]
  • [Cites] Leukemia. 2009 Jan;23(1):53-8 [18830260.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Blood. 2009 Jan 22;113(4):875-82 [18922853.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1037-45 [19155305.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2245-55 [18988867.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2312-23 [19074734.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1761-70 [19273160.001]
  • [Cites] Leukemia. 2009 Mar;23(3):486-91 [19092854.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Apr;15(4):421-31 [19285629.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jun;58(6):855-65 [18841361.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):427-36 [19225975.001]
  • [Cites] Leukemia. 2009 Apr;23(4):641-8 [19151770.001]
  • [Cites] Transfusion. 2009 Feb;49(2):362-71 [19389215.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jul;58(7):1047-55 [19018534.001]
  • [Cites] Int J Hematol. 2009 May;89(4):460-9 [19360457.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] J Immunother. 2009 May;32(4):408-14 [19342964.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Leuk Res. 2009 Jul;33(7):948-57 [19233469.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1669-77 [19225777.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1679-90 [19283381.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):478-88 [19641204.001]
  • [Cites] Scand J Immunol. 2009 Sep;70(3):194-205 [19703009.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):503-5 [19707241.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1736-45 [19556425.001]
  • [Cites] Cytotherapy. 2009;11(5):653-68 [19530029.001]
  • [Cites] Expert Rev Vaccines. 2009 Oct;8(10):1415-25 [19803762.001]
  • [Cites] Curr Opin Immunol. 2009 Oct;21(5):525-30 [19717293.001]
  • [Cites] Br J Haematol. 2010 Mar;148(6):879-89 [20064159.001]
  • [Cites] Haematologica. 2010 Jul;95(7):1191-7 [20081055.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Cytotherapy. 2006;8(6):554-8 [17148031.001]
  • [Cites] Clin Exp Immunol. 2007 May;148(2):189-98 [17437417.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):186-95 [17593025.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Front Biosci. 2008;13:2022-9 [17981688.001]
  • [Cites] Leuk Res. 2008 Dec;32(12):1842-8 [18614230.001]
  • [Cites] Eur J Haematol. 2008 Oct;81(4):281-8 [18573171.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):372-81 [18205840.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6 [17855129.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):128-34 [17906298.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):407-15 [18058809.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):486-94 [18249062.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3633-43 [10572074.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):709-19 [11378266.001]
  • [Cites] Cancer Immunol Immunother. 2001 Jun;50(4):173-80 [11459169.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3750-6 [11739182.001]
  • [Cites] Clin Exp Immunol. 2001 Dec;126(3):403-11 [11737054.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):383-9 [11839382.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4343-9 [12036860.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2075-82 [12533031.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):442-51 [12580958.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1481-7 [12627513.001]
  • [Cites] Leukemia. 2003 Apr;17(4):716-30 [12682629.001]
  • [Cites] Adv Cancer Res. 2003;90:127-56 [14710949.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Nat Immun Cell Growth Regul. 1983-1984;3(4):165-80 [6597341.001]
  • [Cites] Blood. 1986 Nov;68(5):1030-5 [3768529.001]
  • [Cites] Semin Hematol. 1987 Jan;24(1):40-54 [3547672.001]
  • [Cites] Leuk Res. 1990;14(11-12):967-73 [2280612.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):43-9 [1998596.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):88-99 [2069169.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2158-63 [7919330.001]
  • [Cites] Cell. 1995 Apr 7;81(1):9-12 [7536631.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(9):891-7 [9156262.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):989-99 [9169643.001]
  • [Cites] Leukemia. 1998 Jan;12(1):52-8 [9436920.001]
  • [Cites] Scand J Immunol. 1998 Jan;47(1):54-62 [9467659.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):914-9 [9508173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8639-44 [10411928.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2002-7 [15470487.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1768-73 [16079891.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):152-7 [16611305.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):35-46 [19449004.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):73-9 [19526239.001]
  • [Cites] Curr Gene Ther. 2009 Oct;9(5):396-408 [19860654.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3909-16 [19710498.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2109-17 [19626050.001]
  • [Cites] Haematologica. 2010 Jan;95(1):71-8 [19648166.001]
  • [Cites] J Immunol. 2010 Feb 15;184(4):1885-96 [20089697.001]
  • [Cites] Haematologica. 2010 Mar;95(3):485-93 [19903675.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):451-63 [18261837.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2542-53 [18240144.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):104-9 [18381105.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):889-98 [18494931.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2222-7 [18688847.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):521-41 [18790453.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2924-32 [18790773.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):771-7 [18756547.001]
  • [Cites] Br J Haematol. 2008 Sep;142(6):877-88 [18564358.001]
  • (PMID = 20529084.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 108
  • [Other-IDs] NLM/ PMC2909404
  •  go-up   go-down


7. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood; 2007 May 1;109(9):3658-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
  • The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison.
  • We evaluated our results and those of the previous MRC, BGMT, and EORTC studies in a meta-analysis, which revealed a significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Living Donors. Transplantation Conditioning


8. Tsavaris N, Kopterides P, Kosmas C, Siakantaris M, Patsouris E, Pangalis G: Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment. Leuk Lymphoma; 2006 Mar;47(3):557-60
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment.
  • Spontaneous remission of acute myeloid leukemia (AML) in adults is a rare but well documented phenomenon.
  • This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer.
  • Remission persisted for at least 4 years before the patient was lost to follow-up.
  • To the author' knowledge, this is the first report of remission in an AML-M4 case associated with hormone manipulation.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Myelomonocytic, Chronic / drug therapy. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Middle Aged. Remission, Spontaneous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396781.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


9. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • Myeloid sarcoma is described as tumor mass consisting of myeloblasts or immature myeloid cells, involving extramedullary tissues.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.
  • Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.
  • The patient with AML-M2 continued treatment with polychemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Bhatia N, Wallace T, Divgi A, Short V: Myeloid sarcoma presenting as an isolated nodule in a patient with acute myelogenous leukemia. J Drugs Dermatol; 2007 Apr;6(4):447-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma presenting as an isolated nodule in a patient with acute myelogenous leukemia.
  • We report a case of an elderly female in remission from acute myelogenous leukemia that presented with a nonhealing enlarging asymptomatic nodule on her right thigh.
  • A wide excision of the nodule and histological examination revealed myeloid sarcoma without evidence or overlap of leukemia cutis, which had been suspected from nodules that had developed early in the course of the disease.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Radiotherapy. Treatment Outcome


11. Rubnitz J, Inaba H, Ribeiro R, Pounds S, Pui C, Leung W: Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • We hypothesized that the transplantation of purified haploidentical NK cells may be a safe and effective form of consolidation therapy that will reduce the risk of relapse among children with acute myeloid leukemia (AML) who are not treated with HSCT.
  • In this pilot study, we assessed the safety, feasibility, and engraftment of NK cell infusions in 10 patients with AML in first remission.
  • RESULTS: The 10 patients had a median age of 2.5 years (range, 8 months to 21 years) and a median leukocyte count of 62 x 10<sup>9</sup>/L (range, 4 to 487) at diagnosis.
  • One patient had prolonged NK engraftment (189 days), but no non-hematological toxicity.
  • Grade 3-4 non-hematological toxicity was limited to one respiratory viral infection and one episode of febrile neutropenia.
  • With a median follow-up time of 637 days, all patients remain in remission.
  • CONCLUSIONS: Haploidentical NK cells can be safely administered to AML patients who are in remission.
  • We have recently opened a new trial to evaluate the efficacy of NK cell therapy in children in first remission of AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ: Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol; 2005 Jul;130(2):233-48
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
  • Cancer subtype diagnosis using microarray signatures has the potential to transform pathological diagnosis but the routine measurement of genes signatures remains difficult.
  • Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) was used to determine gene signatures.
  • The expression profile of the 17 top-ranked genes distinguishing AML and ALL were measured by RT-PCR in five ALL, 26 AML, 12 AML remission, four chronic myeloid leukaemia (CML) and nine morphologically normal BM samples.
  • All but two of the genes measured showed similar expression in AML and ALL to that reported previously.
  • Specifically, c-MYB (P </= 0.04) was significantly increased in ALL in the total fraction, whilst HOXA9 (P </= 0.19) and cystatin c (P </= 0.01) were increased in AML in the CD34(+) and CD34(-) fractions, respectively. c-MYB, hSNF2, RBAP48, HKRT-1, LYN, CD33, Adipsin and HOXA9 were increased in AML compared with remission AML, indicating an ability to determine disease activity.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029452.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA, Neoplasm
  •  go-up   go-down


13. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W: Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood; 2009 Jan 29;113(5):1002-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
  • Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity.
  • Among older AML patients (age > 60 years), there are few long-term survivors.
  • Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality.
  • We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality.
  • We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chromosomes, Human, Pair 13 / genetics. Leukemia, Myeloid, Acute / drug therapy. Thalidomide / analogs & derivatives. Trisomy / genetics
  • [MeSH-minor] Aged. Humans. Male. Remission Induction / methods

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Trisomy 13.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):335-9 [18202658.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71 [12469764.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1614-21 [1698482.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Leukemia. 2006 Mar;20(3):426-32 [16424866.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):89-95 [16616042.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1123-6 [17650443.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1308-16 [17485549.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1900-10 [17786921.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] Semin Hematol. 2002 Jul;39(3 Suppl 2):4-10 [12214287.001]
  • (PMID = 18824593.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00466895/ NCT00546897
  • [Grant] United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / K23CA120708
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2947363
  •  go-up   go-down


1
Advertisement
4. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood; 2010 Jul 15;116(2):171-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
  • A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia in complete remission but with molecular evidence of WT1 transcript.
  • With a mean follow-up of 30 plus or minus 8 months after diagnosis, median disease-free survival has not been reached.
  • Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia, Myeloid, Acute / therapy. Oncogene Proteins / therapeutic use. Vaccination / methods. WT1 Proteins / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cytotoxicity, Immunologic. Disease-Free Survival. Female. HLA-A Antigens / genetics. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Hypersensitivity, Delayed / immunology. Interferon-gamma / biosynthesis. Interferon-gamma / immunology. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Vaccines, Subunit / genetics. Vaccines, Subunit / immunology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6047-55 [11086036.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1037-42 [14504104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):740-9 [9833768.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):721-8 [16010587.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1318-23 [15920488.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1415-8 [15845894.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1324-32 [16219568.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):34-42 [16397021.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):850-60 [16220325.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):231-6 [16611662.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1293-8 [16533527.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55 [17671141.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1781-7 [10688838.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1613-6 [18256684.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):995-1002 [19176197.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • (PMID = 20400682.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00398138
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / PHS HHS / / P01 23766
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Oncogene Proteins; 0 / Vaccines, Subunit; 0 / WT1 Proteins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2910606
  •  go-up   go-down


15. Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK, Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D: Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. Acta Haematol; 2008;119(2):111-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality.
  • A 35-year-old female patient was diagnosed with acute myeloid leukemia with multiple genetic aberrations [48 XX, del(3)(q21), +6, t(11;15)(q23;q15), +21] including an 11q23/MLL abnormality.
  • The patient achieved a complete remission after one induction chemotherapy cycle.
  • A bone marrow aspirate revealed 55% leukemic blasts carrying the unfavorable genetic aberrations seen at initial diagnosis (11q23/MLL).
  • In the absence of any disease-specific treatment, the leukemic blasts cleared from the bone marrow within 6 days after diagnosis of relapse and peripheral blood counts returned to normal.
  • This is the first report of spontaneous remission in a patient with initially a multiaberrant leukemic cell clone and a proven 11q23/MLL abnormality at relapse after HCT.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / pathology. Myeloid-Lymphoid Leukemia Protein / genetics
  • [MeSH-minor] Adult. Bone Marrow Examination. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Recurrence. Remission, Spontaneous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18367831.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


16. de Greef GE, van Putten WL, Boogaerts M, Huijgens PC, Verdonck LF, Vellenga E, Theobald M, Jacky E, Löwenberg B, Dutch-Belgian Hemato-Oncology Co-operative Group HOVON, Swiss Group for Clinical Cancer Research SAKK: Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol; 2005 Jan;128(2):184-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
  • Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies.
  • This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols.
  • In the same patient group, the presence of extramedullary leukaemia, incomplete platelet (<100 x 10(9)/l) or neutrophil (<1.0 x 10(9)/l) recovery caused a reduced OS and increased RR.
  • In conclusion, < or =5% blasts in the BM, recovery of neutrophils and platelets, and the absence of extramedullary disease constitute the cornerstones for the definition of a haematological CR in patients with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Disease-Free Survival. Female. Humans. Lymphocyte Count. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 Apr;129(1):157-8; author reply 158 [15801968.001]
  • (PMID = 15638852.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


17. Lipton J, Joffe S, Ullrich NJ: CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol; 2008 Nov;39(5):355-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri.
  • An 18-year-old man in remission from acute myelogenous leukemia 3 years after a bone marrow transplant presented with signs of pseudotumor cerebri, including headache, visual changes, and papilledema.
  • He was diagnosed with an isolated central nervous system relapse of acute myeloid leukemia.
  • Although the precise etiology remains elusive, this case demonstrates that pseudotumor cerebri must remain within the differential diagnosis after other complications are excluded, particularly in persons with underlying hematologic malignancies.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Pseudotumor Cerebri / diagnosis. Pseudotumor Cerebri / etiology
  • [MeSH-minor] Adolescent. Biopsy. Diagnosis, Differential. Humans. Male. Recurrence


18. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, Meloni G, Iori AP, Michallet M, Willemze R, Deconninck E, Harousseau JL, Polge E, Rocha V: Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jul 1;26(19):3183-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
  • PURPOSE: Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities.
  • They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses.
  • RESULTS: In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively.
  • Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Chromosome Inversion. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Recurrence. Remission Induction. Retrospective Studies. Statistics, Nonparametric. Surveys and Questionnaires. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Milligan KS, Phillips DL: Perioral numbness associated with intravenous pentamidine administration. Ann Pharmacother; 2007 Jan;41(1):153-6
Hazardous Substances Data Bank. PENTAMIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 56-year-old female with acute myelogenous leukemia in remission developed Pneumocystis carinii infection.

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164393.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 673LC5J4LQ / Pentamidine
  •  go-up   go-down


20. Anderson GA, Braaten K: Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia. Urol Oncol; 2005 Nov-Dec;23(6):419-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia.
  • Extramedullary leukemia (EML) is an uncommon clinical diagnosis in patients with acute nonlymphocytic leukemia (ANLL).
  • Prostatic EML as a first site of ANLL relapse is even more rare.
  • We describe an additional case of prostatic EML as a site of ANLL relapse.
  • An asymptomatic male in ANLL remission was found to have a normal prostate-specific antigen (PSA) and a myeloid leukemic infiltrate in a newly diagnosed prostate nodule.
  • Staging was negative for ANLL relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301120.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Al-Tawfiq JA, Al-Khatti AA: Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum. Int J Lab Hematol; 2007 Oct;29(5):386-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum.
  • Spontaneous remissions of acute myeloid leukemia (AML) have been reported in association with infection.
  • Here, we report a case of spontaneous remission of AML in a 47-year-old Saudi Arabian male patient who presented with a few weeks history of recurrent abdominal pain, vomiting and fever.
  • He was diagnosed with acute monocytic leukemia (AML, FAB M5b) and a perforated bowel.
  • Six weeks later, he achieved spontaneous and complete remission lasting for about 4 months.
  • The remission and relapse were documented by bone marrow examination.
  • Similarly, previous reports of spontaneous remission of AML were short lived and were followed by relapse and progression.
  • [MeSH-major] Clostridium Infections / complications. Clostridium septicum / pathogenicity. Intestinal Perforation / complications. Leukemia, Monocytic, Acute / complications
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824921.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I: Cytarabine-induced fever complicating the clinical course of leukemia. Anticancer Drugs; 2005 Jan;16(1):59-62
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytarabine-induced fever complicating the clinical course of leukemia.
  • The aim of this study is to assess the frequency and clinical characteristics of cytosine arabinoside-induced fever in patients with acute myeloid leukemia in remission, receiving high-dose (3 g/m2) consolidation therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cytarabine / adverse effects. Fever / chemically induced. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613905.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


23. Brkljacic B, Cikara I, Ivanac G, Hrkac Pustahija A, Zic R, Stanec Z: Ultrasound-guided bipolar radiofrequency ablation of breast cancer in inoperable patients: a pilot study. Ultraschall Med; 2010 Apr;31(2):156-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were at high-risk for general anesthesia and surgery because of severely impaired cardiac function, advanced age, or associated diseases (acute myeloid leukaemia (AML), diabetes, hypertension, depression) and/or refused surgery.
  • The Patient with AML and BCA had an infection of the treated breast after 4 months and postponed mastectomy to an AML remission status.
  • There were no signs of malignancy in histopathology; the patient finally died of leukemia 42 months after RFA.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 19941254.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry; 2008 Jan;79(1):52-6
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient was diagnosed with acute myeloid leukaemia (remission 5 years after diagnosis).

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846110.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate; 77238-31-4 / Interferon-beta; BZ114NVM5P / Mitoxantrone; MRK240IY2L / Azathioprine; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood; 2006 Jul 1;108(1):88-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
  • The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR).
  • Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subsequent CR (CR > 1) and randomly assigned to treatment with HDC/IL-2 or no treatment (control).
  • Study arms were balanced for age, sex, previous treatment, leukemic karyotypes, time from CR to inclusion, and frequency of secondary leukemia.
  • These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission.
  • [MeSH-major] Histamine / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556892.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 820484N8I3 / Histamine
  •  go-up   go-down


26. Kinoshita T, Yokokawa M, Yashiro N: Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings. Clin Imaging; 2006 Jul-Aug;30(4):271-4
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings.
  • A rare case of granulocytic sarcoma (GS) of the bilateral breasts after complete remission of acute myelogenous leukemia is reported.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Sarcoma, Myeloid / diagnosis. Ultrasonography
  • [MeSH-minor] Female. Humans. Middle Aged. Rare Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814144.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Mejdoubi M, Huynh A, Danho C, Boot B: Cervical spondylodiscitis caused by Blastoschizomyces capitatus. Infection; 2009 Apr;37(2):153-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 37-year-old woman, during her second remission of acute myeloid leukemia, presented with severe neck pain and cervico-brachial neuralgia.
  • [MeSH-minor] Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Female. Humans. Leukemia, Myeloid, Acute / complications. Neck / diagnostic imaging. Pyrimidines / therapeutic use. Tomography, X-Ray Computed. Triazoles / therapeutic use. Ultrasonography. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Infect Dis. 1990 Jul-Aug;12(4):570-82 [2385764.001]
  • [Cites] Rev Med Interne. 1998 Jun;19(6):431-3 [9775185.001]
  • [Cites] J Rheumatol. 1998 Nov;25(11):2276-8 [9818677.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):358-66 [11170942.001]
  • [Cites] J Infect. 1995 Nov;31(3):251-2 [8586852.001]
  • [Cites] J Clin Microbiol. 2005 Apr;43(4):1818-28 [15815003.001]
  • [Cites] J Clin Microbiol. 1994 Jan;32(1):224-7 [8126186.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):335-41 [14727202.001]
  • (PMID = 18231719.001).
  • [ISSN] 1439-0973
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


28. Numata A, Matsuishi E, Koyanagi K, Saito S, Miyamoto Y, Irie K, Gondo H, Harada M: Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia. Am J Hematol; 2006 Feb;81(2):107-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia.
  • A 43-year-old man with acute myelogenous leukemia (AML) was found to be complicated with pulmonary alveolar proteinosis (PAP), which was confirmed by biochemical and histological findings.
  • After achievement of complete remission of AML, he underwent whole-lung lavages twice between intensive chemotherapies.
  • He has been in remission for 25 months after transplant with no recurrence of PAP.
  • [MeSH-major] Bronchoalveolar Lavage. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation. Pulmonary Alveolar Proteinosis / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Remission Induction / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16432866.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH: Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leuk Res; 2006 Feb;30(2):204-10
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
  • For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m(2)/day, 24h i.v. infusion x 5), mitoxantrone (12 mg/m(2)/day x 3), and etoposide (150 mg/m(2)/day x 3).
  • Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 May;33(5):610-2 [18990445.001]
  • (PMID = 16055185.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


30. Rimner T, Went P, Tichelli A, Gratwohl A: Concomitant hairy cell and acute myeloid leukemia. Eur J Haematol; 2006 Jan;76(1):86-8
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant hairy cell and acute myeloid leukemia.
  • Secondary malignancies in patients with hairy cell leukemia (HCL) are well described and treatment of HCL is discussed as their cause.
  • We describe a 58-yr-old patient who presented with both acute myeloid leukemia (AML) and HCL at the same time.
  • Treatment with cladribine, daunorubicin and cytosine arabinoside, followed by autologous stem cell transplantation, induced complete remission of AML and hematologic remission of HCL for 22 months, when he relapsed with AML.
  • This concomitant occurrence of AML and HCL is suggestive of a genetic predisposition rather then coincidence or relation to purine analoga.
  • [MeSH-major] Leukemia, Hairy Cell / pathology. Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343277.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


31. Kim JY, Song HJ, Lim HJ, Shin MG, Kim JS, Kim HJ, Kim BY, Lee SW: Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission. Mol Cell Proteomics; 2008 Feb;7(2):431-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission.
  • To investigate whether serum biomarkers can be used to indicate the responsiveness of acute myeloid leukemia to remission induction chemotherapy, we performed MALDI-TOF protein profile analysis of patient sera.
  • The resulting spectra revealed a protein (or peptide) peak at m/z 7764 that varied in intensity; its intensity was much higher in samples from patients in complete remission than in those from patients with resistant disease or in samples taken prior to treatment (at the time of diagnosis).
  • This study demonstrates that PF4 protein levels are a good indicator for the recovery of blood count in the complete remission of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / drug therapy. Platelet Factor 4 / blood
  • [MeSH-minor] Amino Acid Sequence. Blood Cell Count. Chemical Fractionation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoassay. Magnetics. Male. Microspheres. Middle Aged. Molecular Sequence Data. Platelet Count. Regression Analysis. Remission Induction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998245.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 37270-94-3 / Platelet Factor 4
  •  go-up   go-down


32. Yokoyama H, Harigae H: [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Nihon Rinsho; 2009 Oct;67(10):1974-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
  • It is important for achieving complete remission of acute myelogenous leukemia to manage anemia and bone marrow hypoplasia, which cause serious complications.
  • [MeSH-major] Anemia / etiology. Anemia / therapy. Bone Marrow / pathology. Bone Marrow Diseases / etiology. Bone Marrow Diseases / therapy. Leukemia, Myeloid / complications. Leukemia, Myeloid / therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860200.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Number-of-references] 14
  •  go-up   go-down


33. Hsiao PJ, Kuo SM, Chen JH, Lin HF, Chu PL, Lin SH, Ho CL: Acute myelogenous leukemia and acute leukemic appendicitis: a case report. World J Gastroenterol; 2009 Nov 28;15(44):5624-5
MedlinePlus Health Information. consumer health - Appendicitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia and acute leukemic appendicitis: a case report.
  • Acute myelogenous leukemia (AML) can involve the gastrointestinal tract but rarely involves the appendix.
  • We report a male patient who had 1 year partial remission from AML and who presented with apparent acute appendicitis as the initial manifestation of leukemia relapse.
  • Pathological findings of the appendix revealed transmural infiltrates of myeloblasts, which indicated a diagnosis of leukemia.
  • Although leukemic cell infiltration of the appendix is uncommon, patients with leukemia relapse can present with symptoms mimicking acute appendicitis.
  • [MeSH-major] Appendicitis / complications. Appendicitis / diagnosis. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Aged. Appendectomy. Disease Progression. Granulocyte Precursor Cells / cytology. Humans. Leukemic Infiltration / diagnosis. Leukemic Infiltration / pathology. Male. Recurrence. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 2003;109(4):199-201 [12853694.001]
  • [Cites] Oncology. 1978;35(2):87-96 [274679.001]
  • [Cites] Cutis. 1987 Jan;39(1):57-60 [3802911.001]
  • [Cites] Ann Intern Med. 1964 Dec;61:1084-103 [14233829.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(10):560-4 [9393590.001]
  • [Cites] J Clin Pathol. 1962 Jul;15:305-13 [13881389.001]
  • [Cites] Korean J Intern Med. 1993 Jan;8(1):40-5 [8268146.001]
  • (PMID = 19938205.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2785068
  •  go-up   go-down


34. Katsuya H, Takata T, Ishikawa T, Sasaki H, Ishitsuka K, Takamatsu Y, Tamura K: A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus. J Infect Chemother; 2009 Feb;15(1):39-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus.
  • We report a case of fatal pneumonia caused by B. cereus in a patient with newly diagnosed acute myeloid leukemia (AML) during remission induction therapy.
  • [MeSH-major] Bacillaceae Infections / microbiology. Bacillus cereus / drug effects. Carbapenems / pharmacology. Leukemia, Myeloid, Acute / complications. Pneumonia, Bacterial / microbiology. beta-Lactam Resistance
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Immunocompromised Host. Lung / radiography. Male. Middle Aged. Neutropenia. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280299.001).
  • [ISSN] 1341-321X
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Carbapenems
  •  go-up   go-down


35. Liang T, Tan T, Xiao Y, Yi H, Li C, Peng F, Chen Z, Xiao Z: [Methylation and expression of glioma pathogenesis-related protein 1 gene in acute myeloid leukemia]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 May;34(5):388-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methylation and expression of glioma pathogenesis-related protein 1 gene in acute myeloid leukemia].
  • OBJECTIVE: To detect the methylation and expression of glioma pathogenesis-related protein 1(GLIPR1) gene in the acute myeloid leukemia (AML) cell lines and bone marrow cells from AML patients, and to determine the relationship between promoter methylation and expression of GLIPR1.
  • METHODS: Five leukemia cell lines, 54 bone marrows from the newly diagnosed AML patients, 48 bone marrows from the acute lymphoblastic leukemia (ALL )patients, 40 bone marrows from the chronic myeloid leukemia (CML) patients,35 bone marrows from control patients, and 8 bone marrows from the complete remission AML patients were collected.
  • RESULTS: The level of GLIPR1 mRNA in the AML cell lines was lower than that in the chronic myeloid leukemia (CML) and ALL cell lines, whereas the methylation level of GLIPR1 in the former was higher than that in the latter.
  • The level of GLIPR1 mRNA in the AML cell lines was significantly increased, but had no obvious changes in the CML and ALL cell lines after 5-aza-2dC treatment.
  • The mRNA level of GLIPR1 in the AML bone marrows (0.38+/-0.20)was obviously lower than that in the ALL bone marrows (0.76+/-0.18), CML bone marrows (0.80+/-0.14), and control bone marrows(0.85+/-0.12).
  • The level of GLIPR1 mRNA in the bone marrows with complete remission AML was obviously higher than that in the AML bone marrows before the treatment (0.78+/-0.13 vs. 0.36+/-0.20); but there was no obvious difference between the ALL bone marrows and the control bone marrows, and the CML bone marrows and the control bone marrows (both P>0.05).
  • The positive rate of GLIPR1 gene methylation in the AML bone marrows (81.5%) was obviously higher than that in the ALL bone marrows(37.5%), CML bone marrows (27.5%) and the control bone marrows(14.3%).
  • The positive rate of GLIPR1 gene in the bone marrows with complete remission AML was obviously lower than that in the bone marrows before the treatment (12.5% vs. 75.0%), but there was no obvious difference between the ALL bone marrows and between the control bone marrows,and the CML bone marrows and the control bone marrows (both P>0.05).
  • There was a negative correlation between the mRNA level and methylation status of GLIPR1 in the AML bone marrows.
  • CONCLUSION: GLIPR1 expression is downregulated or even lost by promoter methylation in AML, and the expression and methylation level of GLIPR1 gene may have some significance in evaluating the curative effect of AML patients.
  • [MeSH-major] DNA Methylation. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483285.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger
  •  go-up   go-down


36. Guinn BA, Mohamedali A, Thomas NS, Mills KI: Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother; 2007 Jul;56(7):943-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of myeloid leukaemia.
  • The treatment of myeloid leukaemia has progressed in recent years with the advent of donor leukocyte infusions (DLI), haemopoietic stem cell transplants (HSCTs) and targeted therapies.
  • However, relapse has a high associated morbidity rate and a method for removing diseased cells in first remission, when a minimal residual disease state is achieved and tumour load is low, has the potential to extend remission times and prevent relapse especially when used in combination with conventional treatments.
  • Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are heterogeneous diseases which lack one common molecular target while chronic myeloid leukaemia (CML) patients have experienced prolonged remissions through the use of targeted therapies which remove BCR-ABL(+) cells effectively in early chronic phase.
  • Here we review the immune therapies which are close to or in clinical trials for the myeloid leukaemias and describe their potential advantages and disadvantages.
  • [MeSH-major] Immunotherapy / methods. Leukemia, Myeloid / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180671.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 84
  •  go-up   go-down


37. Fenton C, Perry CM: Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia. BioDrugs; 2006;20(2):137-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia.
  • Gemtuzumab ozogamicin (Mylotarg) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalization, releases a derivative of the cytotoxic calicheamicin component.
  • In the US, it is approved as monotherapy in patients aged>or=60 years with a first relapse of AML who are ineligible for other cytotoxic therapy.
  • Monotherapy with gemtuzumab ozogamicin results in complete remission (CR) or CR with incomplete platelet recovery (CRp) in approximate, equals 25% of adults (including those aged>or=60 years) with CD33-positive AML in first relapse.
  • Preliminary data indicate a potential role for gemtuzumab ozogamicin as a component of induction or consolidation regimens in adults and, based on an early study, in the treatment of children with AML, although randomized, controlled studies are needed.
  • Gemtuzumab ozogamicin is a valuable new treatment option for patients aged>or=60 years with CD33-positive AML in first relapse for whom other cytotoxic chemotherapy is not considered appropriate; patients with a first CR (CR1) of >12 months are likely to have the best outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Drugs. 2005;65(16):2405-27 [16266206.001]
  • (PMID = 16626170.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


38. Bow EJ, Meddings JB: Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia; 2006 Dec;20(12):2087-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia.
  • Intestinal barrier function was prospectively examined in the course of a clinical trial evaluating the efficacy and safety of lisofylline for reducing cytotoxic therapy-induced intestinal epithelial damage-related infectious morbidity in patients receiving standard remission-induction therapy for acute myeloid leukaemia.
  • The absorption and permeation of oral D-Xylose, lactulose and mannitol were measured weekly from baseline until marrow recovery in adult recipients of idarubicin plus cytarabine for untreated acute myeloid leukaemia.
  • These studies were correlated with non-haematologic chemotherapy-related toxicities reflecting mucosal damage, including nausea, vomiting, stomatitis, diarrhoea, abdominal pain and systemic infection.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Infection / etiology. Intestinal Mucosa / drug effects. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Intestinal Absorption / drug effects. Male. Middle Aged. Prospective Studies. Remission Induction. Xylose / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082779.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; A1TA934AKO / Xylose
  •  go-up   go-down


39. Davies SM, Rowe JM, Appelbaum FR: Indications for hematopoietic cell transplantation in acute leukemia. Biol Blood Marrow Transplant; 2008 Jan;14(1 Suppl 1):154-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for hematopoietic cell transplantation in acute leukemia.
  • Based on available data, all adults with AML under age 60 years with matched siblings should be considered for allogeneic transplantation in first remission, except for those with favorable risk cytogenetics and possibly those whose disease has normal cytogenetics and is FLT3/ITD negative and NPM1 positive.
  • Patients with matched siblings not transplanted in first remission should be followed closely so that transplantation in early first relapse can be considered.
  • RIC allogeneic transplantation using either a matched family member or a MUD can be considered for patients age 60 years or greater with AML in second or subsequent remission, or AML in first remission with intermediate or high risk disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8
  • (PMID = 18162237.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  • [General-notes] NLM/ Original DateCompleted: 20080104
  •  go-up   go-down


40. Ogasawara T, Yasuyama M, Kawauchi K: Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol; 2005 Jun;79(2):136-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
  • We describe a patient who developed myelodysplastic syndrome over 2 years after achieving complete remission of acute myeloid leukemia (AML).
  • The patient was treated in July 1998 with anthracycline, etoposide, and behenoyl cytarabine chemotherapy for AML (French-American-British classification, M2; World Health Organization classification, AML with maturation) and achieved complete remission.
  • The pancytopenia progressed rapidly, and he died 2 months after the diagnosis of MDS.
  • Therapy-related MDS and AML (t-MDS/t-AML) developing after treatment for acute leukemia is unusual; the primary leukemia associated with most cases of t-MDS/t-AML is acute promyelocytic leukemia (APL).
  • This unusual case suggests that AML excluding APL should be considered a primary hematologic malignancy for t-MDS/t-AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosomes, Human, Pair 5. Cytarabine / analogs & derivatives. Leukemia, Myeloid, Acute / chemically induced. Monosomy. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / genetics


41. Marisavljevic D, Markovic O, Zivkovic R: An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase. Med Oncol; 2009 Dec;26(4):476-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase.
  • An unusual case of acute myeloblastic leukemia (AML) with indolent clinical course and spontaneous remission in the terminal phase is described.
  • A 63-year-old male has been diagnosed to suffer from AML, subtype M2.
  • Clinical course was slowly progressive ("smoldering" AML).
  • Five years from diagnosis patient exhibited spontaneous remission of the disease, accompanied with disappearance of del(6q) clone.
  • Additional curiosity in this case is the fact that patient's older brother died of acute lymphoblastic leukemia at the age of 71 years.
  • Possible mechanisms of spontaneous remission of AML and genetic predisposition for human leukemia are discussed with a review of the literature.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):375-82 [9684934.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):376-81 [12225396.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):210-2 [8011534.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):423-5 [11529469.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Feb;58(2):181-5 [1551086.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):33-38 [11137558.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):990-8 [8900225.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2205-9 [9395035.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):557-60 [16396781.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):189-94 [15064869.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2055-61 [12357357.001]
  • [Cites] Int J Hematol. 2001 Aug;74(2):173-7 [11594518.001]
  • [Cites] J Natl Cancer Inst. 1969 Mar;42(3):517-24 [4180615.001]
  • [Cites] Eur J Haematol. 2004 Jul;73(1):62-6 [15182340.001]
  • [Cites] Int J Lab Hematol. 2007 Oct;29(5):386-9 [17824921.001]
  • [Cites] Eur J Haematol. 2004 Sep;73(3):219-22 [15287921.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):561-7 [10492080.001]
  • (PMID = 19130323.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Moon HW, Shin S, Kim HY, Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Chun H, Kim HC, Park CJ, Min YH, Lee DS: Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia; 2006 Aug;20(8):1408-13
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
  • We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).
  • Interestingly, most of these cases had AML with AML1/ETO rearrangement.
  • To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).
  • The number of AML1/ETO+ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO- AML cells (2673 vs 522).
  • This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement.
  • We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791271.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


43. Lo WP, Kuo CL, Kuo MT, Fang PC: Isolated conjunctival myeloid sarcoma as a presenting sign of acute leukemia. Chang Gung Med J; 2010 May-Jun;33(3):334-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated conjunctival myeloid sarcoma as a presenting sign of acute leukemia.
  • Myeloid sarcoma is known as a tumor mass of myeloblasts or immature myeloid cells occurring in an extramedullary site.
  • When ophthalmic areas are involved, it is usually located in the orbits and noted at or after the diagnosis of an underlying leukemia.
  • We report a 38 year-old woman who had isolated conjunctival myeloid sarcoma without any other clinical signs and symptoms.
  • Acute myeloid leukemia (AML) was diagnosed after a thorough examination.
  • The patient had complete remission of AML after systemic chemotherapy.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584512.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


44. Kilic G, Boruban MC, Bueco-Ramos C, Konoplev SN: Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy. Eur J Gynaecol Oncol; 2007;28(4):270-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy.
  • Granulocytic sarcoma is an extramedullary tumor associated with acute myelogenous leukemia (AML) and it is rarely seen in the female genital tract.
  • We report an unusual case of granulocytic sarcoma of the uterus and fallopian tube in an AML patient who presented with vaginal bleeding and persistent abdominal pain.
  • Biopsy did not reveal the diagnosis.
  • Pathology showed atypical myeloid cells infiltrating the muscle bundles which was consistent with granulocytic sarcoma involving the uterus and right fallopian tube.
  • Immunohistochemistry confirmed the diagnosis.
  • The patient is in complete remission for AML and being followed-up for granulocytic sarcoma.
  • Granulocytic sarcoma of the uterus and fallopian tube is very rare, and in AML patients with abnormal uterine bleeding but negative endometrial biopsy it should still be considered in the differential diagnosis.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713090.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M, Miglino M, Clavio M, Risso M, Frassoni F, Bacigalupo A: Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant; 2007 Aug;40(4):349-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.
  • We assessed the outcome of 170 patients with AML in first complete remission, aged 1-47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n=80 and n=90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years.
  • Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined (cyclosporine+methotrexate) GVHD prophylaxis.
  • In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. Humans. Infant. Italy / epidemiology. Male. Neoplasm Recurrence, Local / therapy. Remission Induction / methods. Risk. Survival Analysis. Transplantation, Homologous


46. Knapper S: FLT3 inhibition in acute myeloid leukaemia. Br J Haematol; 2007 Sep;138(6):687-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 inhibition in acute myeloid leukaemia.
  • Activating mutations of FLT3 are present in approximately one-third of acute myeloid leukaemia patients and are associated with adverse clinical outcome, while many non-mutated cases also show evidence of FLT3 activation.
  • FLT3 inhibition may also be effective used in combination with other molecularly targeted agents, in postchemotherapy stem-cell-directed maintenance therapy and in MLL-rearranged infant acute lymphoblastic leukaemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17655729.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HSP90 Heat-Shock Proteins; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 89
  •  go-up   go-down


47. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, Stockelberg D, Wahlin A, Aström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F, Swedish Adult Acute Leukemia Registry Group: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia; 2006 Jan;20(1):42-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
  • Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking.
  • The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown.
  • The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries.
  • Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (chi-squared for trend=11.3, P<0.001; r2=0.86, P<0.02, nonparametric).
  • Differences could not be explained by demographics, and was found in both de novo and secondary leukemias.
  • Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
  • [MeSH-major] Attitude of Health Personnel. Leukemia, Myeloid / drug therapy. Patient Selection
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Registries. Remission Induction. Survival Rate. Sweden / epidemiology. Treatment Outcome


48. Meng YS, Wei R, Ai GW, Meng XQ, Zhang YX: [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia]. Zhonghua Yi Xue Za Zhi; 2009 Apr 7;89(13):890-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia].
  • OBJECTIVE: To explore the expression of the transcription factors LMO2 and LYL1 and the interaction between these 2 factors in myeloid leukemia cells and to analyze the significance thereof in leukemogenesis.
  • METHODS: Samples of peripheral blood and bone marrow were collected form 51 AML patties, and 5 normal bone marrow donors to isolate mononuclear cells (MNCs) with high percentage of CD34(+) cells.
  • Human myeloid leukemia cells of the line K562 were cultured and transfected with pcDNA3-LMO2, plasmid containing LMO2, pcDNA3-LYL1, plasmid containing LYL1, or pcDNA-GFP, blank plasmid containing green fluorescent protein.
  • RESULTS: The MNCs of 51.1% of the patients with acute myeloblastic leukemia (AML) without remission expressed higher levels of LMO2, the MNCs of 62.2% of the AML patients expressed higher levels of LYL1, and the MNCs of 31.1% of those expressed both.
  • The K562 cells transfected with pcDNA3-LMO2 showed higher mRNA and protein expression levels of both LMO2 and LYL1, and the K562 cells transfected with pcDNA3-LYL1 showed higher mRNA and protein expression levels of both LYL1 and LMO2 too, as indicated by RT-PCR and WB, which suggested that the expression of LMO2 and the expression of LYL1 stimulated each other in the myeloid leukemia cells.
  • CONCLUSION: The abnormal expression and protein interaction of LMO2 and LYL1 may play a role in the abnormal proliferation and differentiation of myeloid hematopoietic cells.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Metalloproteins / genetics. Neoplasm Proteins / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671288.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / LYL1 protein, human; 0 / Metalloproteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


49. Bareford D, Odeh B, Narayanan S, Wiltshire S: Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med; 2005 Oct;15(5):445-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin.
  • A 40-year-old patient, who was a Jehovah's Witness, with acute myeloid leukaemia entered remission using a chemotherapeutic based regime aided by the addition of gemtuzumab ozogamicin without requiring any blood product support.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Jehovah's Witnesses. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202062.001).
  • [ISSN] 0958-7578
  • [Journal-full-title] Transfusion medicine (Oxford, England)
  • [ISO-abbreviation] Transfus Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  •  go-up   go-down


50. Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA: Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma; 2006 Aug;47(8):1583-92
Hazardous Substances Data Bank. Samarium, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
  • In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.
  • Complete cytogenetic and morphologic remission of AML was evident on follow-up marrow aspirate and biopsy specimens from all patients.
  • In two of the four study patients, the disease remains in complete remission and the patients have an excellent quality of life (Eastern Cooperative Oncology Group performance status 0; no medications) and no organ toxicity more than 2 years and more than 4 years, respectively, after their blood and bone marrow transplantations.
  • Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Bone Marrow / radiation effects. Dose-Response Relationship, Radiation. Humans. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Quality of Life. Remission Induction / methods. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966270.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
  •  go-up   go-down


51. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T: The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol; 2010 Sep;23(3):379-90
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of multiparameter flow cytometry for disease monitoring in AML.
  • Monitoring of the minimal residual disease (MRD) load has become essential for the choice of post-induction strategies in patients with acute myeloid leukemia (AML).
  • On the other hand, for most AML patients, multiparameter flow cytometry (MFC) represents a good option for MRD monitoring.
  • In virtually all AML patients, leukemia-associated immunophenotypes (LAIPs) are detectable with MFC.
  • Numerous studies demonstrated the prognostic power of the MRD levels determined by MFC at post-induction as well as post-consolidation time points in adults and children considered to be in hematologic remission of AML.
  • Thus, MFC can significantly contribute to risk assessment of patients with AML during and after treatment and allows clinicians to consider alternative strategies (e.g. allogeneic hematopoietic stem cell transplantation) earlier.
  • Clinical studies need to focus on a standardization of these approaches to facilitate the translation of MFC-based MRD assessment into therapeutic decisions in patients with AML.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21112037.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Schäfer HS, Becker H, Schmitt-Gräff A, Lübbert M: Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer. Leuk Res; 2008 Sep;32(9):1472-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer.
  • Granulocytic sarcoma mimicking a synchronous second primary neoplasm (SPN) constitutes a diagnostic and therapeutic challenge particularly in elderly patients.
  • We report on a 75-year-old female presenting with a Core-binding Factor (CBF) AML of M4eo subtype.
  • However, a biopsy demonstrated granulocytic sarcoma.
  • Since the patient had no comorbidities and had been in excellent performance status until the diagnosis of AML, induction chemotherapy was initiated, with subsequent normalization of bilirubin, CA 19-9, lipase and AP.
  • Complete hematologic remission of AML was attained and the pancreatic mass could not be detected anymore.
  • Following one consolidation treatment, the patient remained in excellent health until relapse occurred 7 months later and she succumbed to AML.
  • In conclusion, AML can rarely mimic the clinical picture of pancreatic cancer.
  • The initially good response of this CBF leukemia highlights the principal usefulness of aggressive induction chemotherapy also in older AML patients, if they are carefully selected not only according to biological risk factors such as cytogenetics, but also to "host factors" (good performance status, lack of comorbidities, etc.).
  • [MeSH-major] Core Binding Factors / metabolism. Leukemia, Myeloid, Acute / diagnosis. Pancreatic Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Aged. Alkaline Phosphatase / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bilirubin / metabolism. CA-19-9 Antigen / metabolism. Carboplatin / therapeutic use. Diagnosis, Differential. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Lipase / metabolism. Magnetic Resonance Imaging


53. Hoshino T, Matsushima T, Saitoh Y, Yamane A, Takizawa M, Irisawa H, Saitoh T, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: Sacroiliitis as an initial manifestation of acute myelogenous leukemia. Int J Hematol; 2006 Dec;84(5):421-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacroiliitis as an initial manifestation of acute myelogenous leukemia.
  • We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML).
  • Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with Sacroiliitis.
  • Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis.
  • However, the sacroiliitis relapsed when the leukemia cells progressed thereafter.
  • The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient.
  • Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML.
  • No previous report has described sacroiliitis as the initial manifestation of de novo AML.
  • [MeSH-major] Leukemia, Myeloid, Acute. Sacroiliac Joint. Spondylitis, Ankylosing
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Blast Crisis / diagnosis. Blast Crisis / diagnostic imaging. Blast Crisis / therapy. Bone Marrow Transplantation. Fatal Outcome. Female. Humans. Radiography. Recurrence. Transplantation, Homologous


54. Kolitz JE: Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol; 2006 Sep;134(6):555-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for acute myeloid leukaemia.
  • Improvements in survival in adult acute myeloid leukaemia (AML) have yet to be gleaned from either refinements in the understanding of the pathophysiology of the disease or from the expanding pool of targeted therapies.
  • Ongoing and planned trials will assess the effects of drugs targeting biological pathways whose clinical importance may vary as a function of the unique genotype and phenotype of each case of AML.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Humans. Immunotherapy. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848792.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 165
  •  go-up   go-down


55. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • Haematological remission was obtained on day 33 of induction treatment (on time).
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


56. Craddock C, Tauro S, Moss P, Grimwade D: Biology and management of relapsed acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):18-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and management of relapsed acute myeloid leukaemia.
  • Disease relapse remains the major cause of treatment failure in adults with acute myeloid leukaemia (AML).
  • This reflects both the failure of current salvage regimens and the absence of effective strategies to secure long-term disease-free survival in those patients who achieve a second remission.
  • As a result, a range of novel drug and transplant therapies has become available in patients with relapsed AML, and it is realistic to anticipate that a co-ordinated assessment of their clinical and biological impact will provide the basis for the design of future, more effective treatments in relapsed disease.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / contraindications. Humans. Immunologic Factors / therapeutic use. Recurrence. Salvage Therapy / methods. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801952.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 156
  •  go-up   go-down


57. Stasi R: Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther; 2008 Apr;8(4):527-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
  • OBJECTIVES: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia.
  • RESULTS/CONCLUSIONS: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia.
  • Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352855.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  • [Number-of-references] 78
  •  go-up   go-down


58. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D, East German Study Group Hematology and Oncology (OSHO): Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia; 2009 Apr;23(4):635-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
  • Between 1996 and 2004, a total of 708 patients were enrolled in the acute myeloid leukaemia (AML) '96 and '02 studies of the East German Study Group (OSHO).
  • In all, 77 (56%) achieved complete remission 1 (CR1) after induction chemotherapy and were eligible for haematopoietic cell transplantation (HCT).
  • HCT was performed after a median of two cycles of consolidation chemotherapy (CT) in the AML '96 and one cycle in the AML '02 study (P=0.03).
  • Treatment-related mortality was low and not statistically significantly different between the two treatment groups (15+/-7 and 5+/-5% for HCT and chemotherapy, respectively; P=0.49).We conclude that early HCT from related or unrelated donors led to significantly better OS and leukaemia-free survival compared with chemotherapy in patients with unfavourable karyotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / mortality. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151786.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


59. Al-Mawali A, To LB, Gillis D, Hissaria P, Mundy J, Lewis I: The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. Int J Lab Hematol; 2009 Feb;31(1):61-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia.
  • Immunophenotyping of acute myeloid leukaemia (AML) has controversial implications with regards to prognosis.
  • The aims of the present study were to determine the frequency of leukaemia-associated phenotypes (LAP) in AML and to correlate their presence with response to induction chemotherapy.
  • We analysed bone marrow samples at diagnosis from 84 AML patients using triple staining flow cytometry with routine standard panel of monoclonal antibodies.
  • In conclusion, our data show the presence of LAP in AML is an independent predictor for response to induction chemotherapy and risk of relapse and should be considered for counselling patients and planning therapy.
  • [MeSH-major] Immunophenotyping. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / immunology. Female. Flow Cytometry. Humans. Male. Middle Aged. Predictive Value of Tests. Remission Induction. Risk Factors. Treatment Failure. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143870.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


60. Zhong LY, Li QH, Huang ZL, Lin W, Lu ZS, Weng JY, Wu SJ, Du X: Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia. Ai Zheng; 2009 Jun;28(6):619-25
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
  • BACKGROUND AND OBJECTIVE: Chemotherapy regimen containing anthracyclines has been used as the standard treatment for acute myeloid leukemia (AML).
  • This study was to compare the efficacy and toxicity of the chemotherapy regimen containing perarubicin (THP) with that containing mitoxantrone (MIT) for young patients with newly diagnosed AML.
  • METHODS: A total of 129 patients with newly diagnosed AML, aged 16 to 60 years olds, were assigned for induction chemotherapy containing one to two courses with standard-dose cytarabine (Ara-C) and an anthracycline antibiotic, THP or MIT.
  • When complete remission was achieved after induction therapy, the patients received two courses of consolidation therapy identical to the induction regimen.
  • Maintenance treatment continued for three years when patients were in continuous complete remission (CCR).
  • CONCLUSIONS: Regimen containing THP plus Ara-C can be used for young adults with newly diagnosed AML for remission induction, but it is not superior to the regimen with MIT.
  • Consolidation chemotherapy with THP or MIT is feasible for young adults with AML after CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Agranulocytosis / chemically induced. Alopecia / chemically induced. Cytarabine / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Nausea / chemically induced. Recurrence. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635200.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; D58G680W0G / pirarubicin
  •  go-up   go-down


61. Gokcan MK, Batikhan H, Calguner M, Tataragasi AI: Unilateral hearing loss as a presenting manifestation of granulocytic sarcoma (chloroma). Otol Neurotol; 2006 Jan;27(1):106-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral hearing loss as a presenting manifestation of granulocytic sarcoma (chloroma).
  • OBJECTIVE: To present a case of acute granulocytic sarcoma of the cerebellopontine angle whose presenting symptom was sudden onset unilateral sensorineural hearing loss.
  • METHODS: A 34-year-old female patient with acute myeloid leukemia on remission admitted because of sudden hearing loss in her right ear for 10 days.
  • Magnetic resonance imaging of the cranium revealed findings consistent with granulocytic sarcoma at the cerebellopontine angle, infiltrating the internal acoustic canal.
  • The patient presented in this report is the first reported case with a granulocytic sarcoma of the cerebellopontine angle who presented with acute sensorineural hearing loss.
  • Despite the rarity of such a case, we would like to emphasize that leukemia must be kept in mind as an etiologic factor in sensorineural hearing loss and suggest that complete blood count and temporal bone imaging be routinely obtained.
  • [MeSH-major] Cerebellar Neoplasms / complications. Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle. Hearing Loss, Sudden / etiology. Sarcoma, Myeloid / complications. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Auditory Threshold. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Paralysis / etiology. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / therapy. Magnetic Resonance Imaging. Treatment Outcome. Vocal Cord Paralysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371856.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


62. Jacobs P, Wood L: Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia. Hematology; 2005 Aug;10(4):321-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia.
  • Cytosine arabinoside and anthracycline-containing regimens induce remission in upwards of 60% of previously untreated patients with adult acute myeloid leukaemia (AML).
  • The patients all received the same drugs in a standard protocol and achievement of complete remission correlated with growth pattern.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Myeloid, Acute / metabolism. Neoplastic Stem Cells / metabolism. Tumor Stem Cell Assay
  • [MeSH-minor] Adolescent. Adult. Cell Survival / drug effects. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Myeloid Progenitor Cells / metabolism. Myeloid Progenitor Cells / pathology. Pilot Projects. Predictive Value of Tests. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085545.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


63. Sajid N, Ahmed N, Khan SR: Congenital leukaemia. J Coll Physicians Surg Pak; 2005 Jan;15(1):52-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital leukaemia.
  • This is a case series of three infants who presented with pallor, bruises, and rashes in first month of their life with non specific symptomatology and were diagnosed to have congenital leukaemia.
  • All were of acute myeloblastic leukaemia (AML) M5-FAB type.
  • [MeSH-major] Leukemia, Myeloid, Acute / congenital
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Infant. Infant, Newborn. Male. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670530.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


64. Kell J: Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials; 2006 May;1(2):103-11
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed acute myeloid leukaemia.
  • Acute myeloid leukaemia (AML) is the most common form of acute leukaemia among adults with an incidence that increases with age.
  • Modern induction chemotherapy will result in complete remission in 50-90% of patients with de novo disease, but between 10 and 25% of patients will have primary refractory disease and the majority of those who gain remission will relapse within 3 years of diagnosis.
  • Treatment of relapsed leukaemia is difficult and well-controlled trials in this group of patients are uncommon.
  • This article reviews the results of published randomised trials in relapse and refractory AML.
  • Questions addressed include the role of high dose cytarabine, with or without the addition of etoposide or mitoxantrone, the use of timed sequential chemotherapy regimens, and growth factors as a means to increase leukaemia cell sensitivity and interference with drug resistance proteins.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / prevention & control

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473961.001).
  • [ISSN] 1574-8871
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Colony-Stimulating Factors; 0 / Immunologic Factors; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 68
  •  go-up   go-down


65. Hamadani M, Awan FT: Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematol Oncol; 2010 Mar;28(1):3-12
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.
  • Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades.
  • However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups.
  • Developing individualized, 'targeted' therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision.
  • Hypothesis-based study designs-from pre-clinical/laboratory experiments to phase-I and subsequent efficacy trials-provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML.
  • Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Combined Modality Therapy. Humans. Prognosis. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645073.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 83
  •  go-up   go-down


66. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B, Forestier E, Heldrup J, Hasle H, Nordic Society for Paediatric Haematology and Oncology (NOPHO): Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol; 2007 Jan;136(2):229-236
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome after relapse in children with acute myeloid leukaemia.
  • In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse.
  • Factors influencing outcome in children with relapsed AML were investigated.
  • The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed.
  • Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%.
  • Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival.
  • Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality.
  • Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1.
  • A significant proportion of children with relapsed AML can be cured, even those with early relapse.
  • Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.
  • [MeSH-major] Leukemia, Myeloid / mortality
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cytarabine / therapeutic use. Cytogenetics. Disease-Free Survival. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Recurrence. Remission Induction. Statistics, Nonparametric. Stem Cell Transplantation. Survival Rate. Sweden. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278259.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


67. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2010 Feb 20;28(6):955-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • PURPOSE To conduct a pilot study to determine the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after an immunosuppressive regimen in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS Ten patients (0.7 to 21 years old) who had completed chemotherapy and were in first complete remission of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for Acute Myeloid Leukemia (NKAML) study.
  • With a median follow-up time of 964 days (range, 569 to 1,162 days), all patients remain in remission.
  • We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Killer Cells, Natural / transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy


68. Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W: Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess; 2010 May;14 Suppl 1:69-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
  • This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of azacitidine (aza) compared with conventional care regimes (CCR) for higher risk patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), based on the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process.
  • The patient outcomes governing relative effectiveness and cost-effectiveness were defined as overall survival, time to progression (TTP) to AML, adverse events and health-related quality of life (HRQoL).
  • It compared aza with CCR in 358 patients with higher risk MDS, CMML and AML 20-30% blasts.
  • The outcomes reported in AZA-001 included overall survival, TTP to AML and adverse events.
  • The results showed that: the median overall survival was 24.5 months on aza, compared with 15.0 months in the CCR group (p = 0.0001); the response rates were low (complete remission 17% aza versus 8% CCR); the median time to transformation to AML was greater in the aza group (17.8 versus 11.5 months; p < 0.0001); and of patients who were red blood cell (RBC) transfusion-dependent at baseline, 45% of those on aza became RBC transfusion-independent during the treatment period, compared with 11.8% in the CCR group (p < 0.0001).
  • The AZA-001 study showed that, compared with CCR, those MDS patients receiving aza had prolonged median survival, had delayed progression to AML, had reduced dependence on transfusions and had a small improvement in response rate.
  • At the time of writing, the guidance appraisal consultation document issued by NICE on 4 March 2010 states that azacitidine is not recommended as a treatment option for people not eligible for haemopoietic stem cell transplantation with the the following conditions: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System, CMML with 10-29% marrow blasts without myeloproliferative disorder, or with AML with 20-30% blasts and multilineage dysplasia, according to World Health Organization classification.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Myelodysplastic Syndromes / drug therapy


69. Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jérome C, Nelken B, de Lumley L, Bertrand Y, Dalle JH, Chevret S, Leblanc T, Baruchel A: Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol; 2008 Nov;143(4):541-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
  • Gemtuzumab ozogamicin (GO) monotherapy is reported to yield a 20-30% response rate in advanced acute myeloid leukaemia (AML).
  • This study examined the efficacy and tolerability of GO combined with cytarabine (GOCYT) in children with refractory/relapsed CD33(+) AML.
  • At the outset of GOCYT, two patients were refractory; eight patients were in refractory first relapse; six patients had relapsed after stem cell transplantation (SCT); and one patient [del(5q) therapy-related AML (t-AML)] had not yet been treated.
  • Ten responses were obtained after GOCYT induction, including complete remission (CR) or CR without complete recovery of platelets (CRp) in six patients (35%).
  • GOCYT combination therapy yielded a high response rate (53%) and showed acceptable toxicity in heavily pretreated children with refractory/relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Aug;146(3):342-4 [19545292.001]
  • (PMID = 18759760.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 04079A1RDZ / Cytarabine
  •  go-up   go-down


70. Sahin FI, Kizilkilic E, Bulakbasi T, Yilmaz Z, Boga C, Ozalp O, Karakus S, Ozdogu H: Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med; 2007 Sep;7(3):102-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients.
  • The role of cytogenetic findings in determining the diagnosis, therapy and prognosis of acute myeloid leukaemia (AML) has become more valuable by the day.
  • In this study, the results of conventional and molecular cytogenetic analyses and clinical outcomes of 66 AML patients of different subgroups aged between 16 and 82 were evaluated.
  • Chromosomal abnormalities were detected in 17 (25.7%) patients cytogenetically at the time of diagnosis, whereas molecular cytogenetic abnormalities were detected in 21 (31.8%) patients by fluorescence in situ hybridisation (FISH).
  • During clinical follow-up, 21 patients (31.8%) achieved complete remission (CR), 2 had partial remission (PR) (3.0%) and 4 patients had progressive disease (6.06%).
  • As for the normal karyotype, each patient displayed a different clinical course, which is probably due to the molecular changes in leukaemia-related genes.
  • Here we report our findings, which correlate with previous reports and conclude that cytogenetics is a crucial marker in leukaemia diagnosis and conventional and molecular cytogenetics should be performed as well as molecular genetic diagnostic methods.
  • [MeSH-major] Leukemia, Myeloid / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cytogenetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1855-8 [15178581.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):235-45 [16207531.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):68-75 [15604894.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Nov;115(1):32-8 [10565297.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):352-8 [12733115.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2526-31 [11895789.001]
  • (PMID = 17972052.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


71. Rajić Z, Colović N, Sretenović M, Plecić M, Janković S, Bakrac M, Colović M: [Hepatosplenic candidiasis in acute leukaemia patients]. Srp Arh Celok Lek; 2008 Jul-Aug;136(7-8):414-8
MedlinePlus Health Information. consumer health - Yeast Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic candidiasis in acute leukaemia patients].
  • INTRODUCTION: Hepatosplenic candidiasis is a disseminated invasive fungal infection that may affects patients with acute leukaemia.
  • CASE OUTLINE: The authors present three patients, two women and one men, aged 23, 26 and 33 years, with acute leukaemia; one with acute myeloblastic and two with acute lymphoblastic leukaemia who developed hepatosplenic candidiasis.
  • The diagnosis was based on prolonged fever, elevated serum bilirubin and alkaline phosphatase, as well as characteristic lesions on computed tomography, nuclear magnetic resonance and ultrasonographic findings and positive blood culture in one patient.
  • Two patients died due to progression of leukaemia.
  • CONCLUSION: If leukaemia patient in remission after chemotherapy develops a prolonged fever of unknown origin, hepatosplenic candidiasis has to be considered and all efforts should be done to diagnose it.
  • The diagnosis is based on clinical presentation and imaging techniques.
  • [MeSH-major] Candidiasis / complications. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Liver Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959179.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


72. Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM: Outcome of acute myeloid leukaemia in adults: a retrospective analysis. Natl Med J India; 2005 Jan-Feb;18(1):12-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
  • BACKGROUND: There are little data from India on the management of acute myeloid leukaemia.
  • With better understanding of the biology of the disease, and routine use of high-dose cytarabine as post-remission therapy with or without haematopoietic blood stem cell transplantation (HSCT), the results have improved in the past two decades.
  • METHODS: A total of 166 newly diagnosed patients with AML (excluding acute promyelocytic leukaemia), 15-60 years of age were treated with daunorubicin (60 mg/m2/day x3 days) or idarubicin (12 mg/m2/day x3 days) with cytarabine (100 mg/m2/day continuous i.v. infusion x7 days) induction chemotherapy.
  • Post-remission therapy included 2 cycles of high-dose cytarabine (15-18 g/m2) followed by monthly cycles of outpatient maintenance chemotherapy x4 cycles, consisting of daunorubicin (45 mg/m2 i.v. x1 day and cytarabine 100 mg/ m2 s.c. twice daily x5 days).
  • Six patients in remission received sibling donor allogeneic HSCT.
  • RESULTS: Morphological complete remission was achieved in 69.9% of the patients.
  • The median duration of remission was 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Idarubicin / administration & dosage. India. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835484.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


73. Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM, Hiddemann W, Bohlander SK, Feuring-Buske M, Braess J, Spiekermann K, Dufour A: Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol; 2008 Oct;143(2):230-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
  • The presence of CCAAT/enhancer binding protein alpha (CEBPA) gene mutations in patients with cytogenetically normal acute myeloid leukaemia (CN-AML) confers a favourable prognosis.
  • Routine screening of all CN-AML patients for CEBPA mutations is therefore important for individual risk-adapted post-remission therapy and requires a fast and easy screening method.
  • We initially evaluated our method by analysing 120 CN-AML samples both by fragment analysis and nucleotide sequencing and reached a sensitivity of 100% and a specificity of 90%.
  • 349 CN-AML samples were subsequently screened for CEBPA mutations by fragment length analysis.
  • Among a total of 469 CN-AML patient samples, 58 CEBPA mutations were detected in 38 CN-AML patients (8.1%).
  • In conclusion, we established a fast and sensitive CEBPA mutation screening method suitable for inclusion in routine AML diagnostics.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. DNA Mutational Analysis / methods. Leukemia, Myeloid, Acute / diagnosis. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752591.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / DNA Primers
  •  go-up   go-down


74. Harani MS, Adil SN, Kakepoto GN, Khilji Z, Shaikh U, Khurshid M: Significance of cytogenetic abnormalities in acute myeloid leukaemia. J Pak Med Assoc; 2006 Jan;56(1):9-13
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of cytogenetic abnormalities in acute myeloid leukaemia.
  • OBJECTIVE: To evaluate the role of karyotype in acute myeloid leukaemia (AML) as a predictor of response to induction chemotherapy.
  • Newly diagnosed patients with denovo AML admitted to the hospital were included in the study.
  • Diagnosis of AML was based on FAB criteria, immunophenotyping and cytogenetic studies.
  • They were treated according to standard protocols (combination of anthracycline and cytarabine -3+7) and those who had acute promyelocytic leukaemia additionally received all- trans retinoic acid (ATRA).
  • Half of the (51.2%) patients out of remaining 41 achieved complete remission on bone marrow examination after receiving induction chemotherapy.
  • In favourable risk group 3/3 (100%) achieved complete remission (CR) while 15/32 (46.9%) in intermediate risk group and 3/6 (50%) in unfavourable risk group.
  • CONCLUSION: The frequency of cytogenetic abnormalities in AML and response to induction chemotherapy was low when compared with international data possibly due to the small sample size.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454127.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


75. Rabbat A, Chaoui D, Montani D, Legrand O, Lefebvre A, Rio B, Roche N, Lorut C, Marie JP, Huchon G: Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol; 2005 May;129(3):350-7
MedlinePlus Health Information. consumer health - Critical Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of patients with acute myeloid leukaemia admitted to intensive care.
  • This retrospective study assessed the prognostic factors associated with early and long-term outcome in consecutive patients with acute myeloid leukaemia (AML) admitted to the intensive care unit (ICU) over a 9-year period.
  • For 68%, admission occurred within the first month following diagnosis of AML.
  • The main reason for ICU admission was an acute respiratory disease in 82% of cases.
  • Factors significantly associated with in-ICU death in multivariate analysis were simplified acute physiology score II and need for invasive MV (IMV).
  • Age, performance status, AML3 subtype and complete remission were significantly associated with 1-year survival.
  • Patients with acute respiratory failure initially supported with non-invasive MV had significantly better ICU outcome than patients initially supported with IMV.
  • In conclusion, ICU admission is justified for selected patients with AML.
  • The ICU mortality rate is highly predictable by the acute illness severity score.
  • [MeSH-major] Critical Care. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Female. Hospital Mortality. Humans. Male. Middle Aged. Prognosis. Respiration, Artificial. Respiratory Insufficiency / etiology. Retrospective Studies. Risk Factors. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842658.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Che Y, Xu YH, Zheng GH, Guo YX: [Clinical significance of HA117 expression in children with acute leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep;40(5):873-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of HA117 expression in children with acute leukemia].
  • OBJECTIVE: To explore the role of the expression of HA117 gene in bone marrow mononuclear cells (BMMNC) with acute leukemia and multidrug resistance.
  • METHODS: HA117 gene expressions in 36 children with acute leukemia and 10 children with Idiopathic thrombocytopenic purpura (ITP) were tested using semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) technique.
  • RESULTS: The HA117 gene was expressed in 75% of children with acute leukemia.
  • There was no significant difference in HA117 gene expression between children with acute lymphoblastic leukemia (ALL, 69.57%) and children with acute myeloid leukemia (AML, 91.67%).
  • But the semi-quantitative expression of HA117/beta-actin in AML childern was significantly higher than in ALL children (q=4.5852, P<0.01).
  • The expressions of HA117 gene and HA117/beta-actin in both ALL and AML children were significantly higher than in ITP children chi2=5.05, 8.81; q=4.4612, 6.9695; P<0.05).
  • The remission patients had lower expression of HA117/beta-actin and similar expression of HA117 compared with initially diagnosed patients.
  • The remission patients had higher expression of HA117 gene and similar expression of HA117/beta-actin compared with patients with ITP.
  • The non-remission patients had higher expression of HA117/beta-actin than remission patients and ITP patients (q=3.1705, 4.4102, P<0.05), but no significant difference from initially diagnosed patients (q=0.5470, P>0.05).
  • CONCLUSION: The expression of HA117 gene is high in the BMMNC of initially diagnosed and non-remission patients with AL.
  • But the remission patients have similar semi-quantitative expression of HA117 as patients with ITP, which indicates that a quantitative testing is more important.
  • HA117 is one of the factors that may affect the clinical remission of AML.
  • The new gene HA117 may also be associated with multidrug resistance of leukemia.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Female. Humans. Infant. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Purpura, Thrombocytopenic, Idiopathic / genetics. Purpura, Thrombocytopenic, Idiopathic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950603.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


82. Chang HH, Lu MY, Jou ST, Lin KH, Tien HF, Wu ET, Lin DT: Neoplastic disorders of hematopoiesis in children with Down's syndrome--a single institution experience in Taiwan. J Formos Med Assoc; 2005 May;104(5):333-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All DS patients aged < 18 years of age with a diagnosis of leukemia or myelodysplastic syndrome (MDS) from 1990 to 2002 were included in this retrospective study.
  • The clinical and laboratory characteristics of patients, including age at diagnosis, gender, initial hemogram, cytogenetic findings, immunophenotype, treatment regimen and outcomes were analyzed.
  • Among them, 9 patients (56%) had acute myeloid leukemia (AML), mainly of the megakaryoblastic subtype.
  • All 8 AML patients who had analyzable metaphase cells revealed clonal chromosomal abnormalities in addition to trisomy 21.
  • Three of these patients developed MDS prior to the onset of AML.
  • Of the 5 patients who underwent chemotherapy, 3 remained in remission with a survival time of 29, 59, and 109 months, and the remaining 2 died as a consequence of chemotherapy toxicity.
  • Among the 6 patients (38%) who developed transient myeloproliferative disorder, 2 were lost to follow-up, 2 died from DS-associated congenital heart abnormalities and 2 survived without any AML changes.
  • The remaining 1 patient (6%) who developed ALL was still in his first remission although this patient suffered profound chemotherapy complications during treatment.
  • CONCLUSIONS: This study found that AML is the most common hematologic neoplasm in Taiwanese children with DS, especially megakaryoblastic leukemia.
  • Long-term remission of AML in DS patients can be achieved with appropriate treatment.

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959600.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


83. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH: Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol; 2005 May;129(3):340-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
  • We assessed the potential of tumour cell/dendritic cell fusion hybrids to generate in vitro anti-leukaemic T-cell responses following co-culture with autologous remission lymphocytes in six patients with acute myeloid leukaemia (AML).
  • Comparison was made to anti-leukaemic responses induced by mature dendritic cells (mDC) co-cultured with autologous, irradiated myeloid blasts.
  • Only one of six patients remission lymphocytes failed to develop leukaemia-directed immune responses following stimulation with either construct.
  • Anti-proliferative properties of fusion hybrids against allogeneic lymphocytes were observed in mixed lymphocyte-leukaemia reactions and were found not to be specific to the cell fusion partners and did not prevent the ability of AML-mDC heterokaryons to induce autologous anti-leukaemic cytotoxicity.
  • We conclude that tumour cell/dendritic cell fusion hybrids hold promise as a cellular vaccine for AML.
  • [MeSH-major] Cancer Vaccines / immunology. Dendritic Cells / immunology. Leukemia, Myeloid / immunology
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Fusion. Cell Proliferation. Coculture Techniques. Cytotoxicity, Immunologic. Female. Flow Cytometry. Humans. Immunophenotyping. Lymphocyte Activation / immunology. Lymphocyte Culture Test, Mixed. Male. Microscopy, Fluorescence. Middle Aged. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842657.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


84. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, Diverio D, Guarini A, Nanni M, Rago A, Cimino G, Alimena G: Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol; 2009 Sep;27(3):148-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
  • Elderly acute myeloid leukaemia (AML) patients have a dismal prognosis due to biological features of disease in itself and to presence of comorbidities.
  • We retrospectively considered the outcome of 120 patients aged >65 years diagnosed as having AML between January 2001 and December 2005.
  • Forty-six patients were treated with intensive chemotherapy and 23 reached a complete remission.
  • Application of CCI and Dombret score may help to better identify patients at diagnosis who can benefit from intensive chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / mortality. Leukocytosis / epidemiology. Myelodysplastic Syndromes / epidemiology. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274612.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


85. Bacchetta J, Douvillez B, Warin L, Girard S, Pagès MP, Rebaud P, Bertrand Y: [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia]. Arch Pediatr; 2008 Aug;15(8):1315-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia].
  • Blueberry Muffin baby is a rare neonatal skin disorder.
  • We report on a newborn presenting with Blueberry Muffin syndrome and an adrenal mass which lead to the diagnosis of neuroblastoma.
  • Actually, it corresponded to an acute monoblastic leukaemia with an adrenal localization and a cerebrospinal fluid involvement.
  • Leukaemia should always be considered in such patients, even in the absence of blasts on white blood cells count and bone marrow examination, as in this patient.
  • This observation was also unusual due to spontaneous remission.
  • The patient is in complete remission at 1 year follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute. Skin Diseases / congenital
  • [MeSH-minor] Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Remission, Spontaneous. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595669.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E, Finnish Leukaemia Group: Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol; 2007 Jun;78(6):477-86
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
  • OBJECTIVE: To investigate the long-term outcome of idarubicin- and cytarabine-based intensive chemotherapy in adult acute myeloid leukaemia (AML).
  • PATIENTS AND METHODS: A total of 327 consecutive patients with de novo AML (promyelocytic leukaemia excluded) aged 16-65 yr were recruited into the study between September 1992 and December 2001.
  • After remission achievement with the first (conventional cytarabine) or second (high-dose cytarabine) chemotherapy cycle, three intensive consolidation courses each containing high- or intermediate-dose cytarabine were given.
  • RESULTS: A total of 268 patients (82%) achieved complete remission (CR).
  • The 5-yr survival was 71%, 47% and 37% for the non-transplanted patients (n = 202) with favourable, intermediate/normal and intermediate/abnormal karyotypes, respectively, while only 8% of the patients having adverse karyotype were alive at 5 yr (P < 0.01).
  • CONCLUSIONS: Idarubicin- and cytarabine-based intensive chemotherapy regimen is very effective in de novo AML for adult patients up to 65 yr of age.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391337.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, German Acute Myeloid Leukaemia Cooperative Group, Study Alliance Leukemia Investigators: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet; 2010 Dec 11;376(9757):2000-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
  • BACKGROUND: About 50% of patients (age ≥60 years) who have acute myeloid leukaemia and are otherwise medically healthy (ie, able to undergo intensive chemotherapy) achieve a complete remission (CR) after intensive chemotherapy, but with a substantially increased risk of early death (ED) compared with younger patients.
  • METHODS: Multivariate regression analysis was used to develop risk scores with or without knowledge of the cytogenetic and molecular risk profiles for a cohort of 1406 patients (aged ≥60 years) with acute myeloid leukaemia, but otherwise medically healthy, who were treated with two courses of intensive induction chemotherapy (tioguanine, standard-dose cytarabine, and daunorubicin followed by high-dose cytarabine and mitoxantrone; or with high-dose cytarabine and mitoxantrone in the first and second induction courses) in the German Acute Myeloid Leukaemia Cooperative Group 1999 study.
  • Risk prediction was validated in an independent cohort of 801 patients (aged >60 years) with acute myeloid leukaemia who were given two courses of cytarabine and daunorubicin in the Acute Myeloid Leukaemia 1996 study.
  • FINDINGS: Body temperature, age, de-novo leukaemia versus leukaemia secondary to cytotoxic treatment or an antecedent haematological disease, haemoglobin, platelet count, fibrinogen, and serum concentration of lactate dehydrogenase were significantly associated with CR or ED.
  • INTERPRETATION: The scores for acute myeloid leukaemia can be used to predict the probability of CR and the risk of ED in older patients with acute myeloid leukaemia, but otherwise medically healthy, for whom intensive induction chemotherapy is planned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Internet. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Germany. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Multivariate Analysis. Predictive Value of Tests. Prognosis. Regression Analysis. Remission Induction. Risk Assessment. Risk Factors. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1967-8 [21131041.001]
  • (PMID = 21131036.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  • [Investigator] Fuss H; Hennesser D; Potenberg J; Ludwig WD; Schöndube D; Späth-Schwalbe E; Hesse-Amojo S; Mayr A; Grüneisen A; Boewer C; Derwahl M; Englisch HJ; Rick O; Siegert W; Notter M; Uharek L; Thiel E; Dörken B; Arnold R; Huhn D; Knigge O; Kolloch R; Krümpelmann U; Weh AJ; Zumsprekel A; Teschendorf C; Stechstor M; Trenn G; Wörmann B; Pflüger KH; Wolff T; Hertenstein B; Thomssen H; Peyn A; Rasche H; Heidtmann HH; Marquard F; Hähnel M; Fiedler F; Herbst R; Hallek M; Staib P; Heike M; Niederste-Hollenberg A; Pielken H; Hindahl H; Röllig C; Schaich M; Thiede C; Kramer M; Ehninger G; Aul C; Giagounidis A; Lange W; Kuhlemann SE; Flasshove M; Karow J; Gramatzki M; Helm G; Fuchs R; Schlegel F; Saal JG; Serve H; Kiehl M; Höffkes HG; Arland M; Meckenstock G; Giagounidis A; Haase D; Trümper L; Griesinger F; Gropp C; Depenbusch R; Eimermacher H; Schütte W; Haak U; Fasshaür E; Schmitz N; Stuhlmann R; Braumann D; Schmidt H; Buhrmann K; Balleisen L; Schubert J; Dürk H; Burk M; Ho AD; Mahlknecht U; Lange JG; Schmitz-Hübner U; Bartholomäus A; Fauser A; Link H; Hagmann FG; Wolf M; Ritter B; Frieling T; Planker M; Köchling G; Hartmann F; Middeke H; Gründgens C; Constantin C; Schalk KP; Jost KA; Fetscher S; Schmielau J; Wagner T; Uppenkamp M; Hoffmann M; Hehlmann R; Lengfelder E; Neubauer A; Schwonzen M; Spangenberg H; Bodenstein H; Tischler J; Graeven D; Kohl D; Heuer T; Pohlmann H; Brack N; Nibler K; Fleckenstein D; Haferlach T; Haferlach C; Schnittger S; Kern W; Emmerich B; Dengler R; Schlag B; Hiddemann W; Braess J; Spiekermann K; Berdel WE; Büchner T; Kienast J; Mesters R; Müller-Tidow C; Krug U; Koschmieder S; Volpert S; Wieacker P; Sauerland MC; Heinecke A; Köpcke W; Wilhelm M; Wandt H; Schäfer-Eckart K; Hirsch F; Seeber B; Hartlapp J; Hegge T; Peceny R; Koch O; Innig G; Südhoff T; Wagner T; Maschmeyer G; Kreuser ED; Schenk M; Reichle A; Andreesen R; Huff H; Schönberger D; Geer T; Heissmeyer H; Labenz J; Gassmann W; Gaske T; Käsberger J; Aulitzky WE; Leimer L; Clemens MR; Mahlberg R; Frickhofen N; Fuhr HG; Schwerdtfeger R; Augener W; Engberding R; Winter R; Sandmann M; Einsele H; Weissinger F; Rückle-Lanz H; Brugger W; Papakonstantinou G; Kreibich U; Schott G; Sommer S; Zschille W
  •  go-up   go-down


88. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, Waterfall M, Samuel K, Yin J, Johnson P, Turner M: Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol; 2006 Apr;133(2):152-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.
  • Twenty-two patients with acute myeloid leukaemia were recruited into a phase I/II clinical trial investigating the vaccination of patients in complete remission (CR) with autologous dendritic-like leukaemia cells (DLLC).
  • At trial entry, leukaemia cells were harvested and tested for their ability to undergo cytokine-induced dendritic cell differentiation.
  • Five patients achieved both CR and had leukaemia cells that successfully underwent differentiation and therefore proceeded to vaccination.
  • Increases in anti-leukaemic T-cell responses were demonstrated in four patients, but only two of the five remained in remission more than 12 months postvaccination.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Dendritic Cells / transplantation. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Feasibility Studies. Female. Humans. Hypersensitivity, Delayed. Interferon-gamma / biosynthesis. Lymphocyte Count. Male. Middle Aged. Neoplasm, Residual. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology. Treatment Outcome. Vaccination / adverse effects. Vaccination / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Aug;134(4):445-6; author reply 446-7 [16822293.001]
  • (PMID = 16611305.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


89. van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM: Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. Handb Exp Pharmacol; 2009;(188):319-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
  • Immunotherapy for leukaemia patients, aiming at the generation of anti-leukaemic T cell responses, could provide a new therapeutic approach to eliminate minimal residual disease (MRD) cells in acute myeloid leukaemia (AML).
  • Alternatively, monocyte derived DC obtained at time of complete remission loaded with leukaemia-specific antigens can be used as vaccine.
  • Several sources of leukaemia-associated antigen and different methods of loading antigen onto DC have been used in an attempt to optimize antitumour responses including apoptotic cells, necrotic cell lysates and tumour-associated pep-tides.
  • Currently, the AML-derived cell line MUTZ-3, an immortalized equivalent of CD34(+) DC precursor cells, is under investigation for vaccination purposes.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Cancer Vaccines. Dendritic Cells / transplantation. Immunotherapy, Adoptive. Leukemia, Myeloid / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031033.001).
  • [ISSN] 0171-2004
  • [Journal-full-title] Handbook of experimental pharmacology
  • [ISO-abbreviation] Handb Exp Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Histocompatibility Antigens
  • [Number-of-references] 186
  •  go-up   go-down


90. Maha A, Cheong SK, Leong CF, Seow HF: Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome. Hematology; 2008 Feb;13(1):13-20
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome.
  • Despite the advances in understanding the pathophysiology of acute myeloid leukaemia (AML), the cure rate for acute myeloid leukaemia patients remains low.
  • However, many AML patients still die.
  • Acute myeloid leukaemia blasts demonstrated differing ability to survive in culture.
  • Thus, this study further supports the hypothesis that AML patients with poor survival may be related to having blasts with a biologically more immature or stem cell-like nature.
  • [MeSH-major] Cell Differentiation. Cell Proliferation. Granulocyte Precursor Cells / pathology. Leukemia, Myeloid, Acute / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Cell Survival. Child. Child, Preschool. Cohort Studies. Female. Humans. In Vitro Techniques. Infant. Male. Middle Aged. Phenotype. Remission Induction. Survival Analysis. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534060.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Pagano L, Pulsoni A, Vignetti M, Tosti ME, Falcucci P, Fazi P, Fianchi L, Levis A, Bosi A, Angelucci E, Bregni M, Gabbas A, Peta A, Coser P, Ricciuti F, Morselli M, Caira M, Foà R, Amadori S, Mandelli F, Leone G, GIMEMA: Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol; 2005 Feb;16(2):228-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials.
  • BACKGROUND: The aim of the study was to evaluate the outcome of acute myeloid leukaemia (AML) in patients with a previous malignancy (sAML) treated with chemo- and/or radiotherapy, enrolled in conventional trials.
  • PATIENTS AND METHODS: In a multicentre setting, a prospective non-concurrent analysis was performed on 2513 new AML patients, aged 12-78 years, consecutively enrolled in EORTC-GIMEMA trials between 1987 and 2001.
  • Thirty-eight patients with sAML were identified and compared with a group of 114 de novo AML patients matched according to age, French-American-British criteria, white blood cell count at diagnosis, trial and time of diagnosis of AML.
  • RESULTS: Comparing the complete remission (CR) rate between 38 sAML patients and 114 de novo AML patients, selected according to the previously reported criteria, we observed no difference in the CR rates [25/38 (66%) versus 66/114 (58%); Pearson chi(2) 0.7393, P=0.390] as well as no differences while comparing the DFS and the OS between the two groups.
  • Similar to de novo AML patients, sAML patients show good response to treatment and the possibility of cure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668275.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Breems DA, Löwenberg B: Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol; 2005 Sep;130(6):825-33
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
  • Most adult patients under 60 years with acute myeloid leukaemia (AML) who achieve a complete remission after induction chemotherapy will relapse if they do not receive further therapy.
  • High-dose cytotoxic therapy followed by autologous SCT or intensive cycles of chemotherapy furnish overall approximately similar probabilities of survival when applied in first remission.
  • Here, we present a concise update regarding the place of autologous SCT in the treatment of AML.
  • Particular issues discussed are the value of autologous SCT in different prognostic subsets of AML and the value of autologous mobilised peripheral blood stem cell transplants, which offer a much faster haematopoietic recovery.
  • [MeSH-major] Leukemia, Myeloid / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adult. Hematopoietic Stem Cell Mobilization. Humans. Peripheral Blood Stem Cell Transplantation / methods. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156852.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


93. Silva PM, Lourenço GJ, Bognone RA, Delamain MT, Pinto-Junior W, Lima CS: Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia. Leuk Res; 2006 Jan;30(1):115-7
MedlinePlus Health Information. consumer health - Genetic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.
  • The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or acute leukaemias is rare.
  • In chronic myeloid leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described associated with the acceleration of disease or onset of blast crisis.
  • We report on a patient with chronic phase of CML and both acquired t(9;22)(q34;q11) and inherited inv(16)(p13q22), who obtained a complete remission of the disease after bone marrow transplant.
  • [MeSH-major] Blast Crisis / pathology. Chromosome Inversion. Chromosomes, Human, Pair 16. Genetic Diseases, Inborn / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Female. Humans. Remission Induction. Translocation, Genetic

  • Genetic Alliance. consumer health - Chromosome 16.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054690.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


94. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Löwenberg B: Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol; 2005 Jan;128(1):59-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
  • The question as to whether autologous stem cell transplantation (SCT) after consolidation chemotherapy improves the probability of survival of patients with acute myeloid leukaemia (AML) in first remission has not been settled.
  • Here, we present the results of a phase III study conducted in newly diagnosed adult AML patients aged <60 years.
  • Patients who had reached a complete remission (CR) after two courses of induction chemotherapy and who were not eligible for a human leucocyte antigen-matched sibling SCT (n = 130), were randomized after a third consolidation cycle of chemotherapy between high-dose cytotoxic treatment and autologous bone marrow transplantation or no further treatment.
  • [MeSH-major] Leukemia, Myeloid / surgery. Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Belgium. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Netherlands. Prospective Studies. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606550.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


95. Hasanbegović E: [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)]. Med Arh; 2006;60(5):315-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)].
  • [Transliterated title] Akutna limfoblastana leukemija kao sekundarni malignom poslije tretmana akutne mijeloicne leukemije (AML/M4).
  • We report about very rare case of ten years old boy with diagnose of acute myeloic leukaemia which was diagnosed in his age of five (March of 2000) at Pediatric Clinic in Sarajevo.
  • In the first phase of the complete remission autologic bone marrow transplantation was done in Italy (Ancona).
  • Just 7 months after transplantation boy had relaps of illness in the form of acute lymphoblastic leukaemia (ALL/L2).
  • Complete therapeutic protocol for acute lymphoblastic leukaemia was done and now boy is in complete clinical and hematologic remission.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Bone Marrow Transplantation. Child. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944736.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


96. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M, Nakamura S, Tomita A, Abe A, Kiyoi H, Kinoshita T, Naoe T: Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol; 2008 Feb;140(4):394-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome.
  • Wnt signaling activates the canonical pathway and induces the accumulation of non-phosphorylated beta-catenin (NPBC) in the nucleus.
  • This study examined the expression of nuclear NPBC in bone marrow specimens from 54 and 44 patients with de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), respectively.
  • On immunohistochemistry with an anti-NPBC antibody, the nuclei were positively stained in 22 and 18 of AML and MDS specimens, respectively.
  • Staining of nuclear NPBC was associated with AML subtypes (M6 and M7), low complete remission (CR) rate, and poor prognosis.
  • These findings suggest that in situ detection of nuclear NPBC by immunohistochemistry could provide new insights into the pathogenesis and prognosis of AML and MDS.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. beta Catenin / metabolism


97. Fenton C, Perry CM: Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs; 2005;65(16):2405-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
  • Gemtuzumab ozogamicin (Mylotarg) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalisation, releases a derivative of the cytotoxic calicheamicin component.
  • In the US, it is approved as monotherapy in patients aged > or =60 years with a first relapse of AML who are ineligible for other cytotoxic therapy.
  • Monotherapy with gemtuzumab ozogamicin results in complete remission (CR) or CR with incomplete platelet recovery (CRp) in approximately =25% of adults (including those aged > or =60 years) with CD33-positive AML in first relapse.
  • Preliminary data indicate a potential role for gemtuzumab ozogamicin as a component of induction or consolidation regimens in adults and, based on an early study, in the treatment of children with AML, although randomised, controlled studies are needed.
  • Gemtuzumab ozogamicin is a valuable new treatment option for patients aged > or =60 years with CD33-positive AML in first relapse for whom other cytotoxic chemotherapy is not considered appropriate; patients with a first CR (CR1) of >12 months are likely to have the best outcome.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] BioDrugs. 2006;20(2):137-9 [16626170.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):522-7 [11673694.001]
  • [Cites] Onkologie. 2004 Feb;27(1):72-82 [15007253.001]
  • [Cites] Pharmacotherapy. 2001 Oct;21(10 ):1175-80 [11601662.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1306-11 [15920495.001]
  • [Cites] Leuk Res. 2003 Oct;27(10 ):893-7 [12860008.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3 Suppl 6):24-31 [11474494.001]
  • [Cites] Blood. 2004 Jan 15;103(2):479-85 [14512295.001]
  • [Cites] J Clin Pharmacol. 2001 Nov;41(11):1206-14 [11697753.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3574-80 [11369653.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4589-97 [12576328.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Drugs Aging. 2002;19(8):571-81 [12207551.001]
  • [Cites] Leukemia. 2005 Oct;19(10 ):1768-73 [16079891.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):443-50 [15231251.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Haematologica. 2001 Aug;86(8):814-20 [11522537.001]
  • [Cites] Leukemia. 2004 May;18(5):983-8 [15029214.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] Haematologica. 2004 Aug;89(8):998-1008 [15339685.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4276-84 [14962898.001]
  • [Cites] Leukemia. 1992 Aug;6(8):776-9 [1640728.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1295-302 [15454492.001]
  • [Cites] J Clin Pharmacol. 2004 Aug;44(8):873-80 [15286091.001]
  • [Cites] Haematologica. 2004 Aug;89(8):950-6 [15339678.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i48-9 [15888751.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):449-52 [13680159.001]
  • [Cites] Leukemia. 2003 Mar;17(3):492-5 [12646936.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1578-82 [12738663.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2310-4 [11895761.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71 [12469764.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1049-55 [9665189.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1466-73 [12689934.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1627-36 [12200674.001]
  • [Cites] Leuk Res. 2005 Jan;29(1):53-7 [15541475.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Leukemia. 2002 May;16(5):813-9 [11986941.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):24-30 [11790976.001]
  • [Cites] Acta Oncol. 2001;40(2-3):231-52 [11441935.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1481-7 [12627513.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10 ):1951-5 [12481890.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):47-58 [11792178.001]
  • [Cites] Leukemia. 2004 Feb;18(2):316-25 [14614514.001]
  • [Cites] Blood. 2001 Aug 15;98 (4):988-94 [11493443.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Eur J Haematol. 2002 Oct;69(4):200-4 [12431238.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90 [12497211.001]
  • [Cites] Drugs. 2001;61(9):1317-22; discussion 1323-4 [11511025.001]
  • [Cites] Blood. 2003 May 15;101(10 ):3868-71 [12543868.001]
  • (PMID = 16266206.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 93NS566KF7 / gemtuzumab
  • [Number-of-references] 72
  •  go-up   go-down


98. Keating GM: Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs; 2009;69(17):2501-18
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
  • Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to International Prognostic Scoring System (IPSS) criteria], chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, or acute myeloid leukaemia (AML) with 20-30% blasts and multilineage dysplasia (according to the WHO classification).
  • Subcutaneous azacitidine is the only drug shown to significantly prolong survival in patients with higher-risk MDS or WHO-defined AML, compared with conventional care (i.e. best supportive care, low-dose cytarabine or intensive chemotherapy).
  • In addition, azacitidine is associated with a lower risk of AML progression and higher rates of complete remission, partial remission, haematological improvement and red blood cell (RBC) transfusion independence.
  • Thus, azacitidine is a valuable option for the first-line treatment of patients with higher-risk MDS/AML.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Combined Modality Therapy. Leukemia, Myeloid, Acute / drug therapy. Prognosis. Risk Assessment
  • [MeSH-minor] Bone Marrow / drug effects. Bone Marrow Cells. Chromosome Inversion. Erythrocyte Transfusion. Erythroid Precursor Cells. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Myelodysplastic Syndromes. Randomized Controlled Trials as Topic. Remission Induction. Stem Cell Transplantation / adverse effects. Transplantation Conditioning / mortality. Treatment Outcome


99. Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C: Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematol Oncol; 2010 Dec;28(4):202-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
  • Acute myeloid leukaemia (AML) secondary to myelodysplastic syndrome (MDS) is characterized by poor prognosis, namely in older patients.
  • The combination of fludarabine (F) with cytarabine (ARA-C) ± G-CSF was proven as effective in patients with poor risk AML.
  • The efficacy and toxicity of a regimen including F + ARA-C as sequential continuous infusion (CI-FLA) in 64 untreated patients aged >60 years, in which AML arose after a previous MDS, was investigated.
  • Overall, 43 patients (67%) achieved complete remission (CR).
  • CI-FLA is effective in elderly patients with AML secondary to previously diagnosed MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / complications
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Diarrhea / chemically induced. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 21136583.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


100. Ferrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F: Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematol Oncol; 2008 Jun;26(2):104-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
  • The percentage of long-term survivors in acute myeloid leukaemia (AML) in the elderly does not exceed 10-15% of patients enrolled into clinical trials because of lower complete remission (CR) rates and higher incidence of relapse.
  • We conclude that the treatment of AML in elderly relapsed patients is extremely heterogeneous.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Italy. Male. Medical Oncology / methods. Middle Aged. Recurrence. Remission Induction. Salvage Therapy. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271064.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement